Hypoxia inducible transcription factors (HIF) are mainly regulated by a group of proline hydroxylases (EGLNs) that, in the presence of oxygen, target HIF for degradation. HIFalpha contains two independent oxygen degradation domains (N-ODD and C-ODD) that are substrates for these enzymes. In this work, we employed the yeast two-hybrid assay to study the sequence determinants required for the binding of EGLN1 and 3 to HIF1alpha in a cellular context. Our results demonstrate that, while EGLN1 is able to recognize both ODDs within full length HIF1alpha protein, EGLN3 only binds to CODD. The analysis of the residue substitutions within CODD uncovered novel critical determinants for EGLN1 and 3 binding. In addition, our results show that both enzymes have a very similar, albeit not identical, residue preference at specific positions in their substrate sequences.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2006.09.170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-ischemic inactivation of HIF Prolyl Hydroxylases in endothelium promotes maladaptive kidney repair by inducing glycolysis.
J Clin Invest
November 2024
Division of Nephrology & Hypertension, Northwestern University Feinberg School of Medicine, Chicago, United States of America.
Article Synopsis
- Ischemic acute kidney injury (AKI) is a frequent issue for hospitalized patients and increases the risk of developing chronic kidney disease (CKD).
- The study identifies the importance of specific enzymes (PHD1, PHD2, and PHD3) in kidney repair after ischemia, revealing that altering these enzymes leads to worse kidney damage and inflammation.
- Inhibiting a protein called MCT4 can improve kidney repair by reducing inflammation and preventing damage caused by a faulty metabolic response in endothelial cells, suggesting a potential treatment strategy for preventing the progression from AKI to CKD.
Genetic Loss of HIF-Prolyl-Hydroxylase 1, but Not Pharmacological Inhibition, Mitigates Hepatic Fibrosis.
Am J Pathol
November 2024
Department of General, Visceral, and Transplantation Surgery, Heidelberg University, Heidelberg, Germany; Department of General, Visceral, Thoracic, and Transplantation Surgery, University of Giessen, Giessen, Germany. Electronic address:
Article Synopsis
- Liver fibrosis results from chronic liver inflammation leading to excess extracellular-matrix production by activated hepatic stellate cells (HSCs), which can lead to serious liver damage.* -
- Research on mice showed that lacking HIF-prolyl-hydroxylase 1 (PHD1) reduced liver fibrosis severity and related inflammation, while treatment with the inhibitor DMOG did not prevent fibrosis.* -
- PHD1 deficiency was linked to decreased activation of HSCs and lower expression of fibrotic and inflammatory markers, suggesting that targeted PHD1 inhibitors might be effective in managing liver fibrosis.*
Adipocyte deletion of the oxygen-sensor PHD2 sustains elevated energy expenditure at thermoneutrality.
Nat Commun
August 2024
Centre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Enhancing thermogenic brown adipose tissue (BAT) function is a promising therapeutic strategy for metabolic disease. However, predominantly thermoneutral modern human living conditions deactivate BAT. We demonstrate that selective adipocyte deficiency of the oxygen-sensor HIF-prolyl hydroxylase (PHD2) gene overcomes BAT dormancy at thermoneutrality.
View Article and Find Full Text PDFHypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
NEJM Evid
September 2024
Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Medicine & Health, Sydney.
Background: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta-analysis, we assessed long-term safety of HIF prolyl hydroxylase inhibitors.
Methods: We searched MEDLINE, Embase, and Cochrane databases for randomized trials comparing HIF prolyl hydroxylase inhibitors with an erythropoiesis-stimulating agent (ESA) or placebo with greater than or equal to 48 weeks of follow-up.
Dihydromyricetin ameliorates experimental ulcerative colitis by inhibiting neutrophil extracellular traps formation via the HIF-1α/VEGFA signaling pathway.
Int Immunopharmacol
September 2024
Key Laboratory of Digestive Diseases, Lanzhou University Second Hospital, Lanzhou, China; Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, China. Electronic address:
Dihydromyricetin (DHM), which has various biological functions, possesses therapeutic potential for ulcerative colitis (UC). Neutrophil extracellular traps (NETs) and their components play a crucial role in several pathological processes in UC. However, whether DHM alleviates UC by regulating NETs remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!